MWNA
XBIT icon

Marshall Wace North America’s XBiotech XBIT Stock Holding History

Marshall Wace North America’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-215
Closed -$2K – 1671
2019
Q1 		$2K Buy
+215
New +$1.74K ﹤0.01% 1505

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Marshall Wace North America's XBIT Position: Q2 2019 in Review

Marshall Wace North America sold out of XBiotech (XBIT) in Q2 2019, closing a stake of 215 shares — an estimated $2K sold.

Marshall Wace North America first reported a position in XBIT in Q1 2019 and held it in 1 quarter. The position peaked at $2K in Q1 2019. 43 funds tracked by Wall St. Rank hold XBIT as of Q2 2019.

  • Marshall Wace North America reported no remaining XBiotech position as of Q2 2019 after selling out during the quarter.
  • Marshall Wace North America sold 215 XBiotech shares in Q2 2019, an estimated $2K.
  • Marshall Wace North America first reported a position in XBiotech in Q1 2019 and held it in 1 quarter.
  • Marshall Wace North America's XBiotech position peaked at $2K in Q1 2019.
  • 43 funds tracked by Wall St. Rank held XBiotech as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.